Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors.

Life science alliance - 1 Mar 2025

Lavallée Émilie, Roulet-Matton Maëline, Giang Viviane, Cardona Hurtado Roxana, Chaput Dominic, Gravel Simon-Pierre

Abstract excerpt

PLK1 inhibitors are emerging anticancer agents that are being tested as monotherapy and combination therapies for various cancers. Although PLK1 inhibition in experimental models has shown potent antitumor effects, translation to the clinic has been hampered by low antitumor activity and tumor relapse. Here, we report the identification of mitochondrial protein signatures that determine the sensitivity to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondria

Share to Polo-Like Kinase 1

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Ribosomal Protein S6 Kinases, 90-kDa

Source

Open in PubMed Open full text

Identifiers

PMID: 39658088
DOI: 10.26508/lsa.202402912
PMCID: PMC11632064

Genes

PLK1
ABCD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors.PMID 39658088Read ↗

Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in MelanomaSemantic proximity Read ↗

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.Semantic proximity Read ↗

Effects of PD-L1 Inhibitors on Mitochondrial Function in Melanoma A375 Cells: Unveiling a Shielded Drug Resistance MechanismSemantic proximity Read ↗

In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 TherapiesSemantic proximity Read ↗

Mitochondrial swap from cancer to immune cells thwarts anti-tumour defencesSemantic proximity Read ↗

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCLSemantic proximity Read ↗

Emerging targets for combination therapy in melanomasSemantic proximity Read ↗

Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatmentSemantic proximity Read ↗

Hijacking the powerhouse: Mitochondrial transfer and mitophagy as emerging mechanisms of immune evasionSemantic proximity Read ↗

Metabolic rewiring in melanoma drug-resistant cells.Semantic proximity Read ↗

Targeting mitochondria in cancer: current concepts and immunotherapy approachesSemantic proximity Read ↗

Mitochondrial signaling pathways and their role in cancer drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.